{"nctId":"NCT01439724","briefTitle":"Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients","startDateStruct":{"date":"2007-06"},"conditions":["Squamous Cell Carcinoma of Nasopharynx","Squamous Cell Carcinoma of Oropharynx","Squamous Cell Carcinoma of Hypopharynx"],"count":94,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Device: Placebo (DMC, São Paulo, Brazil)"]},{"label":"Low Level Laser Therapy","type":"EXPERIMENTAL","interventionNames":["Device: Low Level Laser Therapy- (DMC, São Paulo, Brazil)"]}],"interventions":[{"name":"Low Level Laser Therapy- (DMC, São Paulo, Brazil)","otherNames":["Low Power Laser Therapy","Low Energy Laser Therapy"]},{"name":"Placebo (DMC, São Paulo, Brazil)","otherNames":["Low power laser therapy","Low energy laser therapy"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histological diagnosis of squamous cell carcinoma (nasopharynx, oropharynx and hypopharynx)\n* Candidates for surgery or treatment for organ preservation\n* Performance status (PS) of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG)\n* Indication for radiotherapy and concurrent platinum-based chemotherapy\n* Oral mucosa intact\n* Agree to follow the protocol of oral hygiene\n* Informed consent.\n\nExclusion Criteria:\n\n* Patients using medication for treatment and or prevention of mucositis\n* Patients incapable of treatment compliance or of performing the protocol of oral hygiene","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence and / or Severity of Oral Mucositis","description":"The oral cavities of all patients were evaluated daily, from the first day until the last day of treatment. We used the scales of mucositis of the World Health Organization (WHO) and the Oral Mucositis Assessment Scale (OMAS) and a visual analogue scale (VAS) for pain assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Oral Mucositis Survival Free, Pain, Opioid Treatment, Hospitalization, Treatment Interruption, Treatment Delay, Patient Weight Loss, Nasogastric Tube or of a Gastrostomy.","description":"Oral mucositis survival free, pain, opioid treatment, hospitalization, treatment interruption, treatment delay, patient weight loss, nasogastric tube or of a gastrostomy.The oral cavities of all patients were evaluated, from the first day to the last day of treatment.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":47},"commonTop":["Gastrointestinal disorders"]}}}